Medical/Pharmaceuticals
LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM CONSEQUENCES OF DANGEROUS 'BURN LINES' SOCIAL MEDIA TREND
PARIS, Aug. 5, 2025 /PRNewswire/ -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked wi...
2025-08-05 05:15
1601
Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
MUNICH, Aug. 4, 2025 /PRNewswire/ -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris...
2025-08-04 21:00
2000
Breaking Through Core CT Technology Barriers!
World-Class Innovations to Debut at 2025 Medtec in September SHANGHAI, Aug. 4, 2025 /PRNewswire/ -- A quiet revolution is underway in the field of high-end medical equipment, led byChina's growing innovation power. Core CT technologies, once dominated byinternational giants, are now being steadi...
2025-08-04 16:40
1535
NX Taiwan Awarded Healthy Workplace Certification by "Ministry of Health and Welfare"
- Received High Praise for Promoting Health Management and Contributing to Local Communities - TOKYO, Aug. 4, 2025 /PRNewswire/ -- Nippon Express (Taiwan) Co., Ltd. (hereinafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been accorded Healthy Workplace Certification by t...
2025-08-04 15:00
2123
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 4, 2025 /PRNewswire/ -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canalic...
2025-08-04 14:05
1492
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially acce...
2025-08-04 09:28
2380
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2
Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025
/PRNewswire/ --Alveolus Bio
2025-08-04 08:00
2162
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial inChina for its LY03021, which was filed throughChina's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NE...
2025-08-03 18:23
2816
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall resp...
2025-08-01 21:02
3486
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- On 31st July 2025, a unified consensus document for improving lung cancer care in theAsia-Pacific (APAC) region was officially launched inSingapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive ...
2025-08-01 15:02
2269
Herbalgy Trophy Wraps Up with a Thrilling 1-0 Victory Tottenham for Over Arsenal
Football Fever Grips Hong Kong as nearly 50,000 Fans Pack Kai Tak
Download high-resolution images: http://bit.ly/45dBPVk
2025-08-01 12:59
2770
Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB)
This news is for Australian Media only * Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in p...
2025-08-01 06:01
2004
NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO
NEW YORK, July 31, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-market update + Figma valued at over ...
2025-07-31 20:57
3509
RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other dementias. Highlights include: * Two lifestyle interven...
2025-07-31 19:00
2252
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer
SUZHOU, China, July 31, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study inthe United States (study n...
2025-07-31 18:36
2636
Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines
NEW YORK, July 31, 2025 /PRNewswire/ -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce the launch ofProtecting Our Health (POH), a new think tank that brings together international experts in communication, public...
2025-07-31 02:42
1889
Egg Medical Announces U.S. Patent and Trademark Office Issues Final Rejection of All Claims in Rampart IC's Radiation Shield Patent Following a Reexamination Challenge
ST. PAUL, Minn., July 30, 2025 /PRNewswire/ -- In a significant development in an ongoing legal dispute, the U.S. Patent and Trademark Office (USPTO) has issued a final rejection of all claims in U.S. Patent No. 11,660,056 held by Rampart IC, LLC related to a radiation shielding device. The decis...
2025-07-30 22:24
2791
Emerald Clinical Trials Confirms CEO Transition and Continuity Plan
SINGAPORE, July 30, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. Mary Gunn has stepped down effective immediately. The Board has appointedGlenn Kerkhof, a long-standing Board member and experienced CRO exec...
2025-07-30 20:00
2349
Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company
- First global out-licensing deal since founding — tangible return on new drug development investments - Significant milestone payments and future revenue expected — additional out-licensing of proprietary technologies anticipated SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- Dx&Vx (DXVX) ha...
2025-07-30 20:00
2506
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
Key Takeaways * Participating in the Supplemental Nutrition Assistance Program (SNAP) may help protect against age-related cognitive decline, suggests an analysis of a national study. * Compared to non-participants, SNAP participants had a slower decline in cognitive function during the 10-y...
2025-07-30 19:00
2075
Week's Top Stories
Most Reposted
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 301 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 295 media titles]
2026-01-22 15:16
Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women's and Children's Healthcare in India
[Picked up by 276 media titles]
2026-01-20 09:00
